The phase III neoadjuvant GeparOcto trial (NCT02125344) randomized patients with triple negative breast cancer (TNBC) to receive treatment with intensified dose-dense epirubicin (E), paclitaxel (P), and cyclophosphamide (C; iddEPC) or weekly paclitaxel/liposomal doxorubicin (PM), plus carboplatin (Cb). Data on germline mutational analysis of patients with TNBC and the correlation with pathological complete response (pCR ypT0/is ypN0) were analysed.
NGS-based germline mutational analysis of BRCA1/2 and further 16 BC predisposition or candidate predisposition genes was carried out in 393 patients (iddEPC n = 194, PMCb n = 199). Deleterious (IARC class 4/5) variants were validated by Sanger sequencing. Detection of copy number variations (CNV) was carried out using an in-house CNV detection tool and established open access tools. Validation of CNVs was performed by either multiplex ligation-dependent probe amplification or real-time PCR.
Overall, 69 of 393 (17.6%) patients carry pathogenic mutations in the BRCA1/2 genes. In 324 BRCA1/2-negative patients, 30 patients carry mutations in at least one of the 16 further analysed genes (9.3%). Of those, two patients carry mutations in two genes (ATM/CHEK2, PALB2/XRCC2) and 28 carry mutations in one gene (n = 2 BARD1, n = 5 BRIP1, n = 1 CHEK2, n = 9 FANCM, n = 1 NBN, n = 8 PALB2, n = 1 RAD50, n = 1 RAD51C); no mutations were found in CDH1, MRE11A, PTEN, RAD51D, STK11, and TP53). Overall patients with a BRCA1/2 mutation had a pCR of 69.6% vs 46.0% without a mutation (p < 0.001). In the iddETC group, patients with a BRCA1/2 mutation had a pCR of 64.7% vs 45.0% without a mutation (p = 0.040); in the PMCb arm, patients with a BRCA1/2 mutation had a pCR of 74.3% vs 47.0% without a mutation (p = 0.005).
Our data confirm that BRCA1/2 germline mutations represent a predictive biomarker for the achievement of pCR following neoadjuvant anthracycline-taxane-containing chemotherapy for TNBC.
German Breast Group (GBG).
German Breast Group (GBG).
A. Schneeweiss: Honoraria: Roche, Celgene, AstraZeneca, Novartis, and Pfizer during the past 2 years. C. Hanusch: Consulting or advisory role: Novartis, Roche, Amgen, and Celgene during the past 2 years; Speakers’ bureau: Novartis, Roche, Amgen, Pfizer, and Celgene during the past 2 years. V. Müller: Honoraria: Amgen, AstraZeneca, Daiichi Sankyo, Eisai, Pfizer, Novartis, Roche, and Teva during the past two years; Consulting or advisory role: Hexal, Roche, Pfizer, Amgen, Daiichi Sankyo, Nektar, and Eisai during the past 2 years; Travel, accommodation, or other expenses paid or reimbursed: Roche and Pfizer during the past 2 years. K. Luebbe: Consulting or advisory role: Roche and Novartis during the past 2 years. S. Loibl: Honoraria: Pfizer and Roche during the past 2 years (institution); Consulting or advisory role: Novartis, Pfizer, Roche, and SeaGen during the past 2 years (institution); Research project funding: Abbvie, Amgen, AstraZeneca, Celgene Novartis, Pfizer, Roche, SeaGen, Teva, and Vifor during the past 2 years (institution). All other authors have declared no conflicts of interest.